A new CRC immunotherapy combination trial was announced today: anti-PD1 + anti-CSF1R combo.
(not recruiting/in clinicaltrials.gov yet – will be tested against 6 tumor types including CRC starting in 2015)
A combination of BMS’s PD-1 inhibitor with 5-Prime Therapeutic’s anti-CSF1R experimental immunotherapy “FPA008”
Their stated rationale:
“FPA008, an antibody that inhibits colony stimulating factor-1 receptor (CSF1R), blocks the activation and survival of monocytes and macrophages. ... Inhibition of CSF1R in many cancers reduces the number of immunosuppressive tumor-associated macrophages (TAMs), thereby facilitating an immune response against tumors.”
“Preclinical data suggest that combining antibodies targeting PD-1 and CSF1R may lead to an enhanced anti-tumor immune response compared to either approach alone in treating cancer.”
http://news.bms.com/press-release/oncol ... -clinical-